サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：腫瘍学および免疫学におけるフローサイトメトリー市場- 世界の産業規模、シェア、動向、競合、機会、予測、2018年-2028年
市場調査レポート
商品コード
1309225

腫瘍学および免疫学におけるフローサイトメトリー市場- 世界の産業規模、シェア、動向、競合、機会、予測、2018年-2028年

Flow Cytometry in Oncology and Immunology Market - Global Industry Size, Share, Trends, Competition, Opportunity, and Forecast, 2018-2028 Segmented By Type, By Technology, By Offering, By Application, By End User, By Region
出版日: | 発行: TechSci Research | ページ情報: 英文 116 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円

こちらのレポートには、数時間（ご購入金額の10%）分のアナリストへの質問／追加調査サービスが含まれております。

腫瘍学および免疫学におけるフローサイトメトリー市場- 世界の産業規模、シェア、動向、競合、機会、予測、2018年-2028年
出版日: 2023年07月01日
発行: TechSci Research
ページ情報: 英文 116 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 目次
概要

腫瘍学および免疫学におけるフローサイトメトリーの世界市場は、予測期間2024～2028年に安定したCAGRの成長が見込まれます。

これは、研究活動におけるフローサイトメトリーの適用範囲の拡大と次世代フローサイトメーターの研究開発によるものと考えられます。世界保健機関（WHO）によると、がんは世界の疾病負担と死亡率の主要原因の1つであり、がんの予防、診断、治療の戦略は依然として世界の取り組みです。腫瘍学および免疫学におけるフローサイトメトリーとは、血液、骨髄、またはその他の組織のサンプル中の細胞の数、生きている細胞の割合、細胞の大きさや形などの特定の特徴、細胞表面上の抗原などの腫瘍マーカーの存在を測定する実験手順を指します。免疫腫瘍学（IO）とは、がんに対する免疫系の機能を研究し、がんと闘う免疫系の能力を向上させる治療法を開発することです。しかし、新しい腫瘍学および免疫学の技術／ツールに対する需要は増加しており、これがさらに腫瘍学および免疫学におけるフローサイトメトリーの世界市場の成長を促進すると予想されます。さらに、治療中および治療後の免疫反応をモニターするための特異的で高感度なツールを見出すための技術開拓や取り組みが、予測数年間における市場の成長を促進すると予想されます。

がん患者の増加

世界的に、がんは一般的な死因の一つです。がん患者の世界の増加は、おそらくがん分子診断薬市場の拡大要因であろう。米国がん協会によると、2021年の米国における新規がん罹患者数は180万人、がん死亡者数は60万人です。

医療関係者は、がんの予防や治療を助けるために悪性細胞を拡大させた結果、治療法や診断サービスを生み出すための研究開発を強化しています。がん免疫療法は、多様な病期の複数の腫瘍型に対する標準治療となりつつあり、病気の再発を減らし、より良い生存を提供しています。食品医薬品局（FDA）によると、複数のがん種の治療効果を評価するため、コンビナトリアル療法を実施するため、新薬開発のためのメカニズム的洞察を得るため、あるいは臨床反応の免疫学的予測因子を同定するために、免疫学的・腫瘍学的治療が成功した複数の臨床試験が実施されています。したがって、これらの治療や開発された治療法は、腫瘍学および免疫学におけるフローサイトメトリーの世界市場の成長を促進する要因となっています。

技術の進歩

より高度な技術の開発には、マスサイトメトリー、イメージングフローサイトメトリー、ゲノムサイトメトリー、スペクトルサイトメトリーなどがあり、単一細胞でより多くの細胞パラメーターを同時に、より高い解像度で特徴付けることにより、免疫反応を研究する能力を拡大しています。研究者によると、免疫系はがん細胞を標的にして破壊することができます。したがって、免疫腫瘍学に基づく治療には、がん患者の免疫反応を高めるためのさまざまなアプローチが含まれます。エフェクター細胞の活性化、腫瘍抗原によるワクチン接種、腫瘍溶解ウイルスの投与、阻害経路や免疫抑制機構の遮断、養子キメラ抗原受容体T細胞療法の使用、防御経路の増幅などです。

最近の動向と製品上市

腫瘍学および免疫学におけるフローサイトメトリーの世界市場の成長は、主要な市場プレイヤーの存在によって示されています。例えば、2022年6月、Becton, Dickinson, and Company社は、International Society for Advancement of Cytometry（ISAC）で新しい細胞選別技術を発表しました。2022年9月、ベクトン・ディッキンソン社は、免疫学、ウイルス学、がん、感染症モニタリングなど様々な分野で活躍する研究者がフローサイトメトリープロセスを改善し、より質の高い実験を短時間で理解できるように設計されたクラウドベースのソフトウェアソリューション、BD調査クラウドを発表しました。さらに、2022年2月、ベクトン・ディッキンソンはCytognos, S.L.を買収し、フローサイトメトリーのポートフォリオを拡大し、Cytognos S.L.の約80名の科学者と専門家の専門知識を獲得しました。

利用可能なカスタマイズ

TechSciリサーチは、所定の市場データを用いて、企業固有のニーズに応じたカスタマイズを提供します。レポートでは以下のカスタマイズが可能です：

企業情報

  • 追加市場参入企業（最大5社）の詳細分析とプロファイリング

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 腫瘍学および免疫学におけるフローサイトメトリーの世界市場展望

  • 市場規模と予測
    • 金額別
  • 市場シェアと予測
    • タイプ別（免疫学、腫瘍学）
    • 技術別（セルベースフローサイトメトリー、ビーズベースフローサイトメトリー）
    • 製品別（試薬、装置、消耗品、ソフトウェア）
    • アプリケーション別（トランスレーショナルリサーチ、臨床研究）
    • エンドユーザー別（病院、診断ラボ、リファレンスラボ、製薬・バイオテクノロジー企業、学術研究機関、受託研究機関、その他）
    • 地域別（北米、欧州、アジア太平洋、南米、中東・アフリカ）
    • 企業別（2022年）
  • 市場マップ
    • タイプ別
    • 技術別
    • 製品別
    • アプリケーション別
    • エンドユーザー別
    • 地域別

第6章 北米の腫瘍学および免疫学におけるフローサイトメトリー市場の展望

  • 市場規模・予測
    • 金額別
  • 市場シェアと予測
    • タイプ別
    • 技術別
    • 製品別
    • アプリケーション別
    • エンドユーザー別
    • 国別
  • 北米国別分析
    • 米国
    • カナダ
    • メキシコ

第7章 欧州の腫瘍学および免疫学におけるフローサイトメトリー市場の展望

  • 市場規模と予測
    • 金額別
  • 市場シェアと予測
    • タイプ別
    • 技術別
    • 製品別
    • アプリケーション別
    • エンドユーザー別
    • 国別
  • 欧州国別分析
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン

第8章 アジア太平洋地域の腫瘍学および免疫学におけるフローサイトメトリー市場の展望

  • 市場規模と予測
    • 金額別
  • 市場シェアと予測
    • タイプ別
    • 技術別
    • 製品別
    • アプリケーション別
    • エンドユーザー別
    • 国別
  • アジア太平洋地域国別分析
    • 中国
    • 日本
    • インド
    • 韓国
    • オーストラリア

第9章 南米の腫瘍学および免疫学におけるフローサイトメトリー市場の展望

  • 市場規模と予測
    • 金額別
  • 市場シェアと予測
    • タイプ別
    • 技術別
    • 製品別
    • アプリケーション別
    • エンドユーザー別
    • 国別
  • 南米：国別分析
    • ブラジル
    • アルゼンチン
    • コロンビア

第10章 中東・アフリカの腫瘍学および免疫学におけるフローサイトメトリー市場の展望

  • 市場規模および予測
    • 金額ベース
  • 市場シェアと予測
    • タイプ別
    • 技術別
    • 製品別
    • アプリケーション別
    • エンドユーザー別
    • 国別
  • MEA：国別分析
    • アラブ首長国連邦
    • サウジアラビア
    • 南アフリカ
    • トルコ
    • エジプト

第11章 市場力学

  • 促進要因
    • がん患者の増加
    • 技術の進歩
    • 最近の開発と製品上市
  • 課題
    • フローサイトメトリー装置の製品コストの高さ
    • 誤った抗体反応

第12章 市場動向と発展

第13章 競合情勢

  • Business Overview
  • Product Offerings
  • Recent Developments
  • Financials（As Reported）
  • Key Personnel
    • Danaher Corporation
    • Merck KGaA
    • Miltenyi Biotec
    • Neo-Genomics Laboratories, Inc.
    • Thermo Fisher Scientific Inc
    • Cell Signaling Technology, Inc
    • Becton, Dickinson and Company
    • Agilent Technologies, Inc.
    • DiaSorin S.p.A（Luminex Corporation）
    • OPKO Health, Inc.

第14章 戦略的提言

目次
Product Code: 15020

Global Flow Cytometry in Oncology and Immunology Market is anticipated to witness a growth of steady CAGR in the forecast period, 2024-2028. This can be ascribed due to the expansion of flow cytometry's applicability in research activities and the development of next-generation flow cytometers. According to the World Health Organization, Cancer is one of the leading causes of disease burden and mortality in the world, and strategies for cancer prevention, diagnosis, and treatment are still a global effort. Flow cytometry in oncology and immunology refers to the laboratory procedure to measure the number of cells, the percentage of live cells, and certain characteristics of cells, such as size and shape, in a sample of blood, bone marrow, or other tissue, the presence of tumor markers, such as antigens, on the surface of the cells. Immuno-oncology (IO) is the study of the immune system's functionality against cancer and the development of treatments that improve the ability of the immune system to fight the disease. However, the demand for new oncology and immunologic techniques/tools is increasing, which is further expected to drive the growth of global flow cytometry in the oncology and immunology market. Additionally, the development of technology and efforts to find specific and sensitive tools to monitor immune responses during and after therapy is thereby expected to drive the growth of the market in the forecast years.

The growing prevalence of cancer cases, the technological advancement with the highest accuracy and precision, and the growing awareness amongst the population globally are projected to propel the growth of the market. However, the high cost of products of flow cytometry equipment is expected to hamper the growth of flow cytometry in the oncology and immunology market in the forecast years.

Rising Prevalence of Cancer Cases

Globally, Cancer is one of the prevalent causes of death. The global increase in cancer cases is probably a factor in the oncology molecular diagnostics market's expansion. In the United States of America in 2021, there were 1.8 million new cases and 0.6 million cancer deaths, according to the American Cancer Society.

Medical professionals are stepping up their research and development efforts to create therapies and diagnostic services as a result of the expansion of malignant cells to aid the prevention and treatment of cancer. Cancer immunotherapy is becoming the standard of care for multiple tumor types at diverse disease stages, providing better survival with reduced disease recurrences. According to Food and Drug Administration (FDA), multiple clinical trials with successful implementation of immunology and oncology treatments are being conducted to evaluate the efficacy of treatments of multiple cancer types, to implement combinatorial therapies, to gain mechanistic insight for new drug development or to identify immune predictors of clinical response. Therefore, their treatment and developed therapies are responsible for propelling the growth of global flow cytometry in the oncology and immunology market.

Advancement in Technology

The development of more advanced technologies includes mass cytometry, imaging flow cytometry, genomic cytometry, and spectral cytometry with an expanded ability to study immune responses by characterizing more cellular parameters simultaneously in single cells with higher resolution. According to the researchers, the immune system can target and destroy cancer cells; therefore, immune-oncology-based therapies cover different approaches to boost the immune response in cancer patients, that range from activation of effector cells, vaccination with tumor antigens, administration of oncolytic viruses, blockage of inhibitory pathways or immunosuppressive mechanisms, use of adoptive chimeric antigen receptor T-cell therapy, and to amplify the protective pathways.

Recent Developments & Product Launches

The growth of global flow cytometry in the oncology and immunology market is witnessed due to the presence of major market players. For instance, in June 2022, Becton, Dickinson, and Company launched its new cell sorting technology at the International Society for Advancement of Cytometry (ISAC). In September 2022, a company, namely Becton, Dickinson, launched BD Research Cloud, a cloud-based software solution designed to improve the flow cytometry process for researchers working in a variety of fields, such as immunology, virology, cancer, and infectious disease monitoring, in order to enable higher-quality experiments with faster time to understand. Additionally, in February 2022, Becton, Dickinson acquired Cytognos, S.L. and expanded its flow cytometry portfolio, and gained the expertise of ~80 scientists and professionals at Cytognos S.L.

Market Segmentation

Global Flow Cytometry in Oncology and Immunology Market can be segmented by type, technology, offering, application, end user, region, and company. Based on type, the market can be segmented into immunology and oncology. Based on technology, the market is fragmented into cell-based flow cytometry and bead-based flow cytometry. Based on the offering, the market is segmented into reagents, instruments, and consumables software. Based on application, the market is fragmented into translational research and clinical research. Based on end users, the market is segmented into hospitals, diagnostic laboratories, reference laboratories, pharmaceutical and biotechnology companies, academic research institutes, contract research organizations, and others.

Company Profiles

Danaher Corporation, Merck KGaA, Miltenyi Biotec, Neo-Genomics Laboratories, Inc., Thermo Fisher Scientific Inc., Cell Signaling Technology, Inc., Becton, Dickinson and Company, Agilent Technologies, Inc., DiaSorin S.p.A (Luminex Corporation), OPKO Health, Inc., etc., are some of the key players operating in the global flow cytometry in the oncology and immunology market.

Report Scope

In this report, Global Flow Cytometry in Oncology and Immunology Market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:

Flow Cytometry in Oncology and Immunology Market, By Type:

  • Immunology
  • Oncology

Flow Cytometry in Oncology and Immunology Market, By Technology:

  • Cell-based flow cytometry
  • Bead-based flow cytometry

Flow Cytometry in Oncology and Immunology Market, By Offering:

  • Reagents
  • Instruments
  • Consumables software

Flow Cytometry in Oncology and Immunology Market, By Application:

  • Translational Research
  • Clinical Research

Flow Cytometry in Oncology and Immunology Market, By End User:

  • Hospitals
  • Diagnostic Laboratories
  • Reference Laboratories
  • Pharmaceutical and Biotechnology Companies
  • Academic and Research Institutes
  • Contract Research Organizations
  • Others

Flow Cytometry in Oncology and Immunology Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • UAE
    • Saudi Arabia
    • South Africa
    • Turkey
    • Egypt

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in Global Flow Cytometry in Oncology and Immunology Market.

Available Customizations

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Flow Cytometry in Oncology and Immunology Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (Immunology, Oncology)
    • 5.2.2. By Technology (Cell-based flow cytometry, Bead-based flow cytometry)
    • 5.2.3. By Offering (Reagents, Instruments, and Consumables Software)
    • 5.2.4. By Application (Translational Research, Clinical Research)
    • 5.2.5. By End User (Hospitals, Diagnostic Laboratories, and Reference Laboratories, Pharmaceutical and Biotechnology Companies, Academic Research Institutes, Contract Research Organizations, and Others)
    • 5.2.6. By Region (North America, Europe, Asia Pacific, South America, Middle East and Africa)
    • 5.2.7. By Company (2022)
  • 5.3. Market Map
    • 5.3.1. By Type
    • 5.3.2. By Technology
    • 5.3.3. By Offering
    • 5.3.4. By Application
    • 5.3.5. By End User
    • 5.3.6. By Region

6. North America Flow Cytometry in Oncology and Immunology Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Technology
    • 6.2.3. By Offering
    • 6.2.4. By Application
    • 6.2.5. By End User
    • 6.2.6. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Flow Cytometry in Oncology and Immunology Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By Technology
        • 6.3.1.2.3. By Offering
        • 6.3.1.2.4. By Application
        • 6.3.1.2.5. By End User
    • 6.3.2. Canada Flow Cytometry in Oncology and Immunology Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By Technology
        • 6.3.2.2.3. By Offering
        • 6.3.2.2.4. By Application
        • 6.3.2.2.5. By End User
    • 6.3.3. Mexico Flow Cytometry in Oncology and Immunology Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By Technology
        • 6.3.3.2.3. By Offering
        • 6.3.3.2.4. By Application
        • 6.3.3.2.5. By End User

7. Europe Flow Cytometry in Oncology and Immunology Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Technology
    • 7.2.3. By Offering
    • 7.2.4. By Application
    • 7.2.5. By End User
    • 7.2.6. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Flow Cytometry in Oncology and Immunology Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Technology
        • 7.3.1.2.3. By Offering
        • 7.3.1.2.4. By Application
        • 7.3.1.2.5. By End User
    • 7.3.2. France Flow Cytometry in Oncology and Immunology Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Technology
        • 7.3.2.2.3. By Offering
        • 7.3.2.2.4. By Application
        • 7.3.2.2.5. By End User
    • 7.3.3. United Kingdom Flow Cytometry in Oncology and Immunology Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Technology
        • 7.3.3.2.3. By Offering
        • 7.3.3.2.4. By Application
        • 7.3.3.2.5. By End User
    • 7.3.4. Italy Flow Cytometry in Oncology and Immunology Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By Technology
        • 7.3.4.2.3. By Offering
        • 7.3.4.2.4. By Application
        • 7.3.4.2.5. By End User
    • 7.3.5. Spain Flow Cytometry in Oncology and Immunology Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By Technology
        • 7.3.5.2.3. By Offering
        • 7.3.5.2.4. By Application
        • 7.3.5.2.5. By End User

8. Asia-Pacific Flow Cytometry in Oncology and Immunology Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Technology
    • 8.2.3. By Offering
    • 8.2.4. By Application
    • 8.2.5. By End User
    • 8.2.6. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Flow Cytometry in Oncology and Immunology Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Technology
        • 8.3.1.2.3. By Offering
        • 8.3.1.2.4. By Application
        • 8.3.1.2.5. By End User
    • 8.3.2. Japan Flow Cytometry in Oncology and Immunology Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Technology
        • 8.3.2.2.3. By Offering
        • 8.3.2.2.4. By Application
        • 8.3.2.2.5. By End User
    • 8.3.3. India Flow Cytometry in Oncology and Immunology Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Technology
        • 8.3.3.2.3. By Offering
        • 8.3.3.2.4. By Application
        • 8.3.3.2.5. By End User
    • 8.3.4. South Korea Flow Cytometry in Oncology and Immunology Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By Technology
        • 8.3.4.2.3. By Offering
        • 8.3.4.2.4. By Application
        • 8.3.4.2.5. By End User
    • 8.3.5. Australia Flow Cytometry in Oncology and Immunology Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By Technology
        • 8.3.5.2.3. By Offering
        • 8.3.5.2.4. By Application
        • 8.3.5.2.5. By End User

9. South America Flow Cytometry in Oncology and Immunology Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Technology
    • 9.2.3. By Offering
    • 9.2.4. By Application
    • 9.2.5. By End User
    • 9.2.6. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Flow Cytometry in Oncology and Immunology Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Technology
        • 9.3.1.2.3. By Offering
        • 9.3.1.2.4. By Application
        • 9.3.1.2.5. By End User
    • 9.3.2. Argentina Flow Cytometry in Oncology and Immunology Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Technology
        • 9.3.2.2.3. By Offering
        • 9.3.2.2.4. By Application
        • 9.3.2.2.5. By End User
    • 9.3.3. Colombia Flow Cytometry in Oncology and Immunology Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Technology
        • 9.3.3.2.3. By Offering
        • 9.3.3.2.4. By Application
        • 9.3.3.2.5. By End User

10. Middle East and Africa Flow Cytometry in Oncology and Immunology Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Technology
    • 10.2.3. By Offering
    • 10.2.4. By Application
    • 10.2.5. By End User
    • 10.2.6. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. UAE Flow Cytometry in Oncology and Immunology Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Technology
        • 10.3.1.2.3. By Offering
        • 10.3.1.2.4. By Application
        • 10.3.1.2.5. By End User
    • 10.3.2. Saudi Arabia Flow Cytometry in Oncology and Immunology Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Technology
        • 10.3.2.2.3. By Offering
        • 10.3.2.2.4. By Application
        • 10.3.2.2.5. By End User
    • 10.3.3. South Africa Flow Cytometry in Oncology and Immunology Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Technology
        • 10.3.3.2.3. By Offering
        • 10.3.3.2.4. By Application
        • 10.3.3.2.5. By End User
    • 10.3.4. Turkey Flow Cytometry in Oncology and Immunology Market Outlook
      • 10.3.4.1. Market Size & Forecast
        • 10.3.4.1.1. By Value
      • 10.3.4.2. Market Share & Forecast
        • 10.3.4.2.1. By Type
        • 10.3.4.2.2. By Technology
        • 10.3.4.2.3. By Offering
        • 10.3.4.2.4. By Application
        • 10.3.4.2.5. By End User
    • 10.3.5. Egypt Flow Cytometry in Oncology and Immunology Market Outlook
      • 10.3.5.1. Market Size & Forecast
        • 10.3.5.1.1. By Value
      • 10.3.5.2. Market Share & Forecast
        • 10.3.5.2.1. By Type
        • 10.3.5.2.2. By Technology
        • 10.3.5.2.3. By Offering
        • 10.3.5.2.4. By Application
        • 10.3.5.2.5. By End User

11. Market Dynamics

  • 11.1. Drivers
    • 11.1.1. Rising Prevalence of Cancer Cases
    • 11.1.2. Advancement in Technology
    • 11.1.3. Recent Developments & Product Launches
  • 11.2. Challenges
    • 11.2.1. High Cost of the Products of the Flow Cytometry Equipment
    • 11.2.2. False antibody responses

12. Market Trends & Developments

13. Competitive Landscape

  • 13.1. Business Overview
  • 13.2. Product Offerings
  • 13.3. Recent Developments
  • 13.4. Financials (As Reported)
  • 13.5. Key Personnel
    • 13.5.1. Danaher Corporation
    • 13.5.2. Merck KGaA
    • 13.5.3. Miltenyi Biotec
    • 13.5.4. Neo-Genomics Laboratories, Inc.
    • 13.5.5. Thermo Fisher Scientific Inc
    • 13.5.6. Cell Signaling Technology, Inc
    • 13.5.7. Becton, Dickinson and Company
    • 13.5.8. Agilent Technologies, Inc.
    • 13.5.9. DiaSorin S.p.A (Luminex Corporation)
    • 13.5.10. OPKO Health, Inc.

14. Strategic Recommendations